GSK announced a major leadership transition, naming Chief Commercial Officer Luke Miels as its CEO-designate. He will formally take the helm on January 1, 2026, succeeding Dame Emma Walmsley and leading the company into a new strategic phase focused on specialty medicines and vaccines.
Pfizer has announced a definitive agreement to acquire clinical-stage biopharmaceutical company Metsera in a deal valued at an initial $4.9 billion, with the potential for an additional $2.4 billion in milestone payments. The acquisition is a strategic move to re-enter the lucrative weight-loss drug market by adding Metsera’s next-generation obesity and cardiometabolic disease treatments, including promising oral and injectable therapies, to Pfizer’s pipeline.
Biotechnology giant Amgen is investing over $600 million to build a new research and development hub in Southern California. The cutting-edge facility will bring together top scientific minds to advance the creation of new medicines and is expected to generate hundreds of jobs, reinforcing the company’s commitment to U.S.-based innovation.
New Brunswick, N.J. – Over the next ten years, Johnson & Johnson (JNJ) plans to invest a staggering $2 billion to build a state-of-the-art manufacturing [Read More…]
AbbVie has finalized its acquisition of Capstan Therapeutics, gaining access to a groundbreaking in vivo tLNP CAR-T cell therapy and proprietary RNA delivery platform for B cell-mediated autoimmune diseases.
Omeros Corporation reported a sharply reduced net loss in Q2 2025, strengthened its balance sheet through debt restructuring and new capital, and advanced its lead drug narsoplimab toward regulatory approvals.
Gilead Sciences reports a successful second quarter for 2025, with total revenue climbing to $7.1 billion, driven by a 7% increase in its HIV franchise sales. Diluted EPS rose to $1.56. Following these strong results, Gilead has raised its full-year 2025 guidance, now expecting product sales between $28.3 billion and $28.7 billion.
Eyestem Research has successfully closed an oversubscribed funding round, securing $10 million to accelerate the development of Eyecyte-RPEâ„¢, its investigational cell therapy for dry age-related macular degeneration (dry AMD).
Eli Lilly and Company reported strong second-quarter 2025 financial results, with worldwide revenue increasing 38% to $15.56 billion. This growth was driven by a 42% increase in volume, particularly from the company’s key products Zepbound and Mounjaro. Reported earnings per share (EPS) for the quarter were $6.29, a 92% increase compared to the same period in 2024. Following these results, Lilly has raised its full-year 2025 revenue guidance to a range of $60.0 billion to $62.0 billion.
Pfizer delivered robust Q2 2025 results, reporting $14.7 billion in revenue (up 10% operationally) and $0.78 adjusted EPS. Key drivers included double-digit growth from Comirnaty, Paxlovid and Abrysvo. The company raised its full-year adjusted EPS guidance to $2.90–3.10 while reaffirming revenue outlook of $61.0–64.0 billion, underscoring strong commercial execution and cost-saving initiatives.
